In fact, preclinical data has shown that epcoritamab in combination with venetoclax is associated with increased killing of CLL cells in comparison with epcoritamab or venetoclax alone, especially in samples from patients who progressed while receiving a BTK inhibitor [115]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.